Press Releases

Date Title and Summary Additional Formats
Toggle Summary Anoro(R) (umeclidinium / vilanterol) Receives Positive Opinion From the CHMP in Europe for the Treatment of COPD
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 02/20/14 -- GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive
View HTML
Toggle Summary Anoro(R) (Umeclidinium/Vilanterol) Gains Marketing Authorisation in Europe for the Treatment of COPD
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 05/08/14 -- GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European Commission has granted marketing authorisation for Anoro ® (umeclidinium/vilanterol) as a once-daily,
View HTML
Toggle Summary Anoro(R) Ellipta(R) (Umeclidinium/Vilanterol) Gains Approval in Japan for the Treatment of COPD
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 07/07/14 -- GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Anoro ® Ellipta ® (umeclidinium/vilanterol)
View HTML
Toggle Summary Anoro(TM) Ellipta(R) Now Available in the US for Treatment of COPD
RESEARCH TRIANGLE PARK, NC and SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/28/14 -- GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that Anoro™ Ellipta ® (umeclidinium and vilanterol inhalation powder), the first once-daily product approved in the
View HTML
Toggle Summary ANORO(TM) ELLIPTA(TM) Approved as First Once-Daily Dual Bronchodilator for the Treatment of COPD in the US
LONDON, UK and SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 12/18/13 -- GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ANORO™ ELLIPTA™ as a combination anticholinergic/long-acting beta 2
View HTML
Toggle Summary Astellas and Theravance Announce Approval of VIBATIV(TM) (telavancin) in Canada for the Treatment of Complicated Skin and Skin Structure Infections
VIBATIV(TM) Approved for the Treatment of cSSSI Caused by Susceptible Gram-positive Bacteria, Including MRSA and MSSA Strains
View HTML
Toggle Summary Astellas and Theravance Announce European Marketing Authorization for VIBATIV( R ) for Nosocomial Pneumonia Caused by MRSA
Astellas and Theravance Announce European Marketing Authorization for VIBATIV ® for Nosocomial Pneumonia Caused by MRSA  
View HTML
Toggle Summary Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections in Europe View HTML
Toggle Summary Astellas and Theravance Announce Termination of License, Development and Commercialization Agreement for VIBATIV® (telavancin) for Injection
Astellas and Theravance Announce Termination of License, Development and Commercialization Agreement for VIBATIV ® (telavancin) for Injection
View HTML
Toggle Summary Astellas and Theravance Receive Positive Opinion from CHMP for European Approval of VIBATIV( TM ) for Nosocomial Pneumonia Caused by MRSA View HTML

Copyright Nasdaq. Minimum 15 minutes delayed.

Contact

Innoviva Investor Relations & Media
650.238.9640

For business development inquiries,
please contact bd@inva.com.